Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 5 minute read Pharma Industry News GSK offloads Human Genome Sciences: what’s next for Samsung Biologics’ global ambitions? Samsung Biologics acquires Human Genome Sciences from GSK for $280M, gaining its first U.S. biologics plant. Find out what this move means for global CDMO strategy. byPallavi MadhirajuDecember 22, 2025